Companies: 10,795·Total market cap: $144.5T
Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

XLONASDAQHealthcare● Active
$7.68
$-0.02(-0.26%)
Market Cap$45948204
P/E Ratio—
52W High$12.74
52W Low$6.468
SEC Filings

Xilio Therapeutics, Inc. (XLO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001840233 · XLO · NASDAQ · as of Jun 9, 2026

Filing snapshot

341
Total Filings
EFFECT
Latest Form
2026-05-29
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001840233 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-23
Fiscal Year End
Mar 23, 2026
Accession No.
0001193125-26-118550
Primary Document
xlo-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001840233 · Accession 0001193125-26-118550

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-12Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
EFFECTEFFECT
EFFECT
2026-05-29
View
S-3/AS-3/A
S-3/A
2026-05-27
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
S-3Shelf Registration
S-3
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-12
View
ARSARS
ARS
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
3Initial Statement of Beneficial Ownership
3
2026-04-16
View
8-KCurrent Report
8-K
2026-04-16
View
S-8Employee Stock Plan Registration
S-8
2026-03-23
View
10-KAnnual Report
10-K
2026-03-23
View
Showing 1–15 of 239 filingsForm 4 / 144 hidden· 341 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001840233  |  Exchange: NASDAQ · Healthcare

Xilio Therapeutics, Inc. (NASDAQ: XLO) has submitted 341 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001840233, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Xilio Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Xilio Therapeutics, Inc. 10-K was filed on 2026-03-23 for fiscal year ending 2026. Historical XLO 10-K annual reports are available from 2021 through 2026.

Investors researching Xilio Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
OKUR SEC Filings →PDSB SEC Filings →KZR SEC Filings →LVTX SEC Filings →FGEN SEC Filings →ATNM SEC Filings →ALGS SEC Filings →SKYE SEC Filings →
→ XLO Financials→ XLO Earnings→ XLO Insider Trades

Frequently Asked Questions

XLO SEC Filings · 8 questions

Xilio Therapeutics, Inc. (XLO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 341 filings and access original documents at no cost. Xilio Therapeutics, Inc.'s CIK is 0001840233.

XLO SEC filingsXilio Therapeutics, Inc. SEC documentsfind XLO 10-K